These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 21649448)

  • 21. Pharmacological treatment of acquired QT prolongation and torsades de pointes.
    Thomas SH; Behr ER
    Br J Clin Pharmacol; 2016 Mar; 81(3):420-7. PubMed ID: 26183037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
    Taylor D
    CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
    Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
    Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the potential of clozapine to cause torsade de pointes.
    Warner B; Hoffmann P
    Adverse Drug React Toxicol Rev; 2002; 21(4):189-203. PubMed ID: 12503253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QT alterations in psychopharmacology: proven candidates and suspects.
    Alvarez PA; Pahissa J
    Curr Drug Saf; 2010 Jan; 5(1):97-104. PubMed ID: 20210726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
    Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
    Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Premature atrial contractions with multiple patterns of aberrant conduction followed by torsade de pointes in a patient with polymyalgia rheumatica: A case report.
    Takahashi K; Yamashita M; Sakaue T; Enomoto D; Uemura S; Okura T; Ikeda S; Takemoto M; Utsunomiya Y; Hyodo T; Ochi M; Higuchi S
    Medicine (Baltimore); 2021 Sep; 100(37):e27286. PubMed ID: 34664888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
    Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
    Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inherited long QT syndrome: from ion channel to bedside.
    Vincent GM; Timothy K; Fox J; Zhang L
    Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
    Wolbrette DL
    Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
    Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
    Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety of antipsychotics: a clinical overview.
    Polcwiartek C; Kragholm K; Schjerning O; Graff C; Nielsen J
    Expert Opin Drug Saf; 2016 May; 15(5):679-88. PubMed ID: 26934282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.
    Chan A; Isbister GK; Kirkpatrick CM; Dufful SB
    QJM; 2007 Oct; 100(10):609-15. PubMed ID: 17881416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exercise-induced changes in the QT interval duration and dispersion in patients with sudden cardiac death after myocardial infarction.
    Yi G; Crook R; Guo XH; Staunton A; Camm AJ; Malik M
    Int J Cardiol; 1998 Feb; 63(3):271-9. PubMed ID: 9578355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The best QT correction formula in a non-hospitalized population: the Fasa PERSIAN cohort study.
    Yazdanpanah MH; Naghizadeh MM; Sayyadipoor S; Farjam M
    BMC Cardiovasc Disord; 2022 Feb; 22(1):52. PubMed ID: 35172723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.